February 8, 2020

InterContinental New York Times Square
300 W 44th St.
New York, NY 10036

PER^®’s 16th Annual International Symposium on Melanoma and Other Cutaneous Malignancies^® is a single-day educational conference discussing emerging treatments in melanoma, basal cell carcinoma, squamous cell carcinoma, and Merkel cell carcinoma. This concise and engaging program will inform your practice with insights from world-renowned experts on evolving standards of care in melanoma and other cutaneous malignancies.

Chairs Jeffrey S. Weber, MD, PhD, and Omid Hamid, MD, are the world-renowned experts leading this international program. This fast-paced and interactive forum provides the most concise and complete update for physicians who treat skin cancers. With unmatched access to leading experts in the field, this program provides a forum for improving clinical practice and enables participants to apply the latest research into clinical practice. Sessions will cover the latest advances in immuno-oncology, targeted therapies, regional therapies, and the value of using predictive and prognostic biomarkers. With a special focus on treatment-related adverse event management, this program promises to provide actionable points to improve outcomes for your patients. With dynamic and interactive Medical Crossfire^® discussions, experts will debate key questions in the field and develop evidence-based answers to inform your practice.

One-stop, one day, application

What you will learn:

• The current use of checkpoint inhibitors and other immunotherapeutic strategies, including intralesional therapies, both as single-agent therapy and in combination with other regimens
• Insights into emerging therapeutic targets, including agents targeting LAG3, STING, and other pathways
• Best practices for use of BRAF/MEK inhibitors as single-agent therapy and in combination with other therapies
• Management strategies in the setting of regional disease and metastatic disease
• Strategies for the mitigation of potential adverse events with targeted treatments and checkpoint inhibitors

• Interact with top experts in the field of cutaneous malignancies
• Gain actionable insights to improve the treatment of your patients
• Recognize the role of targeted therapies, checkpoint inhibitors, and combination therapies across the cutaneous malignancies
• Recognize current best practices for management of adverse events with targeted therapies and checkpoint inhibitors
• Network with colleagues and peers

This educational activity is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with skin and other cutaneous malignancies. Dermatologists, dermatopathologists and pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of melanoma and other cutaneous malignancies will be invited to participate.

At the conclusion of this symposium, you should be better prepared to:

• Recognize best practices from the latest clinical trials in cutaneous malignancies to manage the full range of cutaneous malignancies across stages of disease
• Understand best practice for multidisciplinary identification and management of the adverse events associated with treatment across cutaneous malignancies
• Outline best practices for use of biomarkers in personalizing care in patients with melanoma, basal cell carcinoma, squamous cell carcinoma, Merkel cell carcinoma, and other cutaneous malignancies
• Contextualize current evidence in terms of evolving standards of care to support the optimal sequencing of therapies across melanoma, basal cell carcinoma, squamous cell carcinoma, Merkel cell carcinoma, and other cutaneous malignancies

Physicians' Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource^®, LLC designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 6.75 Contact Hours.

This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation,OncoSec Immunotherapies, Inc., Inc., Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme.

Omid Hamid, MD
Chief, Translational Research and Immuno-Oncology
Director, Cutaneous Malignancies
The Angeles Clinic and Research Institute, an affiliate of Cedars Sinai
Director of Experimental Therapeutics
Cedars Sinai Medical Care Foundation
Los Angeles, CA

Jeffrey S. Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, NY